Antigenics Establishes Autologous Cancer Vaccine Collaboration With Sigma-Tau; Sigma-Tau to Partake in Clinical Trials in Italy Using HSP-Based Immunotherapy

NEW YORK, Oct. 13 /PRNewswire/ -- Antigenics, LLC announced today that they have entered into a strategic collaboration with Sigma-Tau, Italy's second largest pharmaceutical company, to launch clinical trials in Italy using Antigenics' proprietary heat shock protein (HSP) vaccines. Sigma-T...

Full description

Saved in:
Bibliographic Details
Published inPR Newswire p. 1
Format Newsletter
LanguageEnglish
Published New York PR Newswire Association LLC 13.10.1998
Subjects
Cancer
Clinical trials
Collaboration
Heat shock proteins
Immunotherapy
Pharmaceutical industry
New York, Italy
Online AccessGet full text

Cover

More Information
Summary:NEW YORK, Oct. 13 /PRNewswire/ -- Antigenics, LLC announced today that they have entered into a strategic collaboration with Sigma-Tau, Italy's second largest pharmaceutical company, to launch clinical trials in Italy using Antigenics' proprietary heat shock protein (HSP) vaccines. Sigma-Tau will provide logistical and financial support for Antigenics' phase II melanoma and colorectal trials to begin in the fourth quarter of 1998 in Milan. Antigenics' lead product, HSPPC-96, is an autologous immunotherapeutic agent designed to boost the body's immune response to cancer. HSPPC-96 is in Phase I/II clinical trials at Memorial Sloan-Kettering and M.D. Anderson Cancer Centers in the US as well as at Johannes Gutenberg University in Mainz, Germany.